Is Egrifta (Tesamorelin) Legal in Colorado? How to Access It Legally
See the public record for Tesamorelin
At a glance
- Drug / Egrifta (tesamorelin acetate), a growth hormone-releasing factor analog
- FDA status / Approved prescription drug, first approved November 10, 2010 (BLA 022505) [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy
- Labeled doses / Egrifta SV 1.4 mg; Egrifta WR 1.28 mg
- Compounding / No FDA category-based statement about compounding it
What is tesamorelin approved for?
Both current labels, dated July 29, 2026, state one indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]. The limitations are that long-term cardiovascular safety has not been established, that the risk and benefit of continuing should be weighed in patients who have not had a reduction in visceral adipose tissue, and that it is not indicated for weight loss management because its effect on weight is neutral [2].
How is it dosed?
The Egrifta SV label gives a dose of 1.4 mg, or 0.35 mL of the reconstituted solution, and says to reconstitute only with the supplied Sterile Water for Injection and give it immediately [2]. The Egrifta WR label gives 1.28 mg, or 0.16 mL, reconstituted with 1.3 mL of Bacteriostatic Water for Injection; one vial supplies seven daily doses and leftover solution is discarded seven days after mixing [3]. Per the labels, both are injected subcutaneously into the abdomen once daily with rotating sites, and the Egrifta SV label says not to inject into scar tissue, bruises or the navel [2][3]. The Egrifta WR label states the two products are not substitutable [3].
Can tesamorelin be compounded?
Tesamorelin is not on FDA's list of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026) and falls in no category of the agency's lists for state-licensed pharmacies and physicians (updated May 14, 2026) or for outsourcing facilities (updated March 21, 2025), so FDA has made no category-based statement about compounding it [4][5][6]. HHS's October 2026 draft enforcement-discretion policy for compounded peptides names six peptides — BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 — and tesamorelin is not among them [7][8]. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing [7][8].
What does the label say to watch for?
The labels contraindicate use in people with disruption of the hypothalamic-pituitary axis, active malignancy, hypersensitivity to tesamorelin or its excipients, or pregnancy [2][3]. Among patients treated 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3; at 52 weeks, those figures were 34% and 23% [2]. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [2].
What about Colorado and sport?
This page establishes the federal position: an approved prescription product with a single labeled indication [1][2]. Whether Colorado has additional rules on accessing it is not established here. Separately, WADA names tesamorelin in S2.2.4 among growth hormone releasing factors and prohibits it at all times, in and out of competition; it is on the 2026 List and stays on the 2027 List [9][10].
Questions worth asking
Frequently asked questions
Is Egrifta (tesamorelin) legal in Colorado?
Does tesamorelin have to be for HIV lipodystrophy?
Is compounded tesamorelin FDA-approved?
What doses do the current labels cover?
Is tesamorelin banned in sport?
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- World Anti-Doping Agency.